Tryp Therapeutics Inc.: Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
La Jolla, California (Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ( Tryp or the Company ) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join the company s Scientific Advisory Board. He will guide Tryp s clinical development of TRP-8802 for neuropathic pain indications. Dr. Castellanos is the lead author of, Chronic pain and psychedelics: a review and proposed mechanism of action , which was published online in
Kennedy Krieger Institute promoted
Melissa Trovato, M.D., to the position of director of rehabilitation.
In this role, Trovato will oversee all medical operations related to pediatric physical medicine and rehabilitation, as well as serve as a liaison with the Department of Physical Medicine and Rehabilitation at the Johns Hopkins University School of Medicine while also working closely with the Institute’s future vice president of physical medicine and rehabilitation.
With more than 20 years of experience at the Institute, Trovato began her career as a pediatric physical medicine and rehabilitation fellow and then became a faculty member in 2001. Throughout her time at Kennedy Krieger, she has taken several leadership roles, serving as the director of inpatient rehabilitation, director of the Pediatric Physical Medicine and Rehabilitation Fellowship, and chair of the Medical Staff Health Information Management Committee. Most recently, in the fall of 2019, Trovato was named th